Tag Archive for: Phase III studies

Boehringer Ingelheim on Monday revealed new Phase II data for its investigational GLP-1/glucagon receptor dual agonist survodutide, showing that it could elicit significant improvements in patients with metabolic dysfunction-associated steatohepatitis.

In two papers published Wednesday in the New England Journal of Medicine, Pfizer touted positive Phase III data for its respiratory syncytial virus (RSV) vaccine candidate, showing high levels of protection for older adults and infants.

PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.

Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.

When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise – including Biogen and Eisai.